Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.

about

Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.

Item

http://www.wikidata.org/entity/Q50050575

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@en

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@nl

type

Item

label

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@en

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@nl

prefLabel

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@en

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@nl

P1476

Efficacy and Safety of Tenelig ...... wo Phase III Clinical Studies.

@en

P2093

Manabu Ishii

http://www.w3.org/2001/XMLSchema#string

Miyuki Matsukawa

http://www.w3.org/2001/XMLSchema#string

Takashi Kadowaki

http://www.w3.org/2001/XMLSchema#string

Yoshiteru Ushirogawa

http://www.w3.org/2001/XMLSchema#string

P2860

Teneligliptin in management of type 2 diabetes mellitus

Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus

Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.

β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians

Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.

P2888

s13300-018-0372-x

P304

623-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-018-0372-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kazuyo Sasaki

P577

2018-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29435909

http://www.w3.org/2001/XMLSchema#string

P932

6104275

http://www.w3.org/2001/XMLSchema#string